Switch to:
Valeant Pharmaceuticals International Inc (NYSE:VRX)
EV/EBITDA
11.35 (As of Today)

EV/EBITDA ratio is calculated as enterprise value divided by its EBITDA. As of today, Valeant Pharmaceuticals International Inc's enterprise value is $45,797 Mil. Valeant Pharmaceuticals International Inc's earnings before depreciation and amortization for the trailing twelve months (TTM) ended in Dec. 2015 was $4,035 Mil. Therefore, Valeant Pharmaceuticals International Inc's EV/EBITDA ratio for today is 11.35.

VRX' s EV/EBITDA Range Over the Past 10 Years
Min: -31   Max: 106.7
Current: 10.46

-31
106.7

During the past 13 years, the highest EV/EBITDA Ratio of Valeant Pharmaceuticals International Inc was 106.70. The lowest was -31.00. And the median was 14.70.

VRX's EV/EBITDA is ranked higher than
75% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.66 vs. VRX: 10.46 )

EV/EBITDA (Enterprise value/EBITDA) is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the P/E Ratio to determine the fair market value of a company.

As of today, Valeant Pharmaceuticals International Inc's stock price is $35.79. Valeant Pharmaceuticals International Inc's earnings per share for the trailing twelve months (TTM) ended in Dec. 2015 was $-0.84. Therefore, Valeant Pharmaceuticals International Inc's P/E Ratio for today is .

The "classic" EV/EBITDA ratio is much better in capturing debt and net cash than the P/E Ratio.


Definition

Valeant Pharmaceuticals International Inc's EV/EBITDA for today is calculated as:

EV/EBITDA=Enterprise Value (Today)/Earnings Before Depreciation and Amortization (TTM)
=45797.065/4035.4
=11.35

Valeant Pharmaceuticals International Inc's current Enterprise Value is $45,797 Mil.
Valeant Pharmaceuticals International Inc's Earnings Before Depreciation and Amortization for the trailing twelve months (TTM) ended in Dec. 2015 was 860.2 (Mar. 2015 ) + 983 (Jun. 2015 ) + 1140.9 (Sep. 2015 ) + 1051.3 (Dec. 2015 ) = $4,035 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

EV/EBITDA (Enterprise value/EBITDA) is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the P/E Ratio to determine the fair market value of a company.

Valeant Pharmaceuticals International Inc's P/E Ratio for today is calculated as:

P/E Ratio=Share Price (Today)/Earnings Per Share (TTM)
=35.79/-0.839
=

Valeant Pharmaceuticals International Inc's share price for today is $35.79.
Valeant Pharmaceuticals International Inc's Earnings Per Share for the trailing twelve months (TTM) ended in Dec. 2015 was 0.21 (Mar. 2015 ) + -0.15 (Jun. 2015 ) + 0.14 (Sep. 2015 ) + -1.039 (Dec. 2015 ) = $-0.84.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Study has found that the companies with the lowest EV/EBITDA outperforms companies measured as cheap by other ratios such as P/E Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Related Terms

Enterprise Value, Earnings Before Depreciation and Amortization, P/E Ratio


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Valeant Pharmaceuticals International Inc Annual Data

Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15
ev2ebitda -22.534.896.066.64113.5522.9626.1336.9417.3717.17

Valeant Pharmaceuticals International Inc Quarterly Data

Sep13Dec13Mar14Jun14Sep14Dec14Mar15Jun15Sep15Dec15
ev2ebitda 45.2536.9435.7228.1819.5917.3725.4926.7322.9417.17
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK